Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Current Size And Growth Outlook For The Apixaban Market?

The apixaban market has seen considerable growth in recent years. It is projected to expand from $2.92 billion in 2024 to $3.16 billion in 2025, with a compound annual growth rate (CAGR) of 8.2%. The historic growth can be credited to factors such as the rising prevalence of atrial fibrillation, an aging demographic, regulatory approvals and market expansions, favorable clinical results, and a transition from warfarin to NOACs.

The market size for apixaban is forecasted to undergo significant expansion in the forthcoming years, projecting a surge to $4.31 billion by 2029 with a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period can be ascribed to continued occurrences of cardiovascular ailments, heightened awareness and diagnosis rates, expansion into nascent markets, the aging worldwide population, and alterations in health policy and reimbursement. Noteworthy trends for the forecast period incorporate advancements in medication delivery systems, burgeoning research and developments, innovation and collaborations, FDA’s approval of apixaban, and the rise of digital health and telemedicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

Which Growth Drivers Are Shaping The Apixaban Market Outlook?

The growth of the apixaban market is projected to be fueled by the increasing incidence of cardiovascular disease. These diseases, which involve the heart and blood vessels, include coronary artery disease, stroke, and heart failure. The spike in such diseases can be attributed to stagnant lifestyles, poor nutrition, smoking, obesity, hypertension, diabetes and older population segments. Apixaban plays a crucial role in the treatment of these diseases as it reduces the chances of blood clots and hence, prevents conditions, such as stroke, deep vein thrombosis, and pulmonary embolism. In January 2024, the American Heart Association, a nonprofit organization in the US, reported that cardiovascular diseases caused 931,578 deaths, indicating an increase of less than 3,000 fatalities when compared to the 928,741 in 2023. Consequently, the increasing occurrence of cardiovascular diseases is spurring the growth of the apixaban market.

What Is The Segment Breakdown Of The Apixaban Market?

The apixaban market covered in this report is segmented –

1) By Dosage Form: Capsule, Tablets

2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Capsule: 2.5 mg Capsule, 5 mg Capsule

2) By Tablets: 2.5 mg Tablet, 5 mg Tablet

How Are Global Trends Impacting The Development Of The Apixaban Market?

Key players in the apixaban market like Tiefenbacher Pharmaceuticals are innovating in their product offerings, with a focus on generic anticoagulant medicine. This approach aims at enhancing both the affordability and availability of drugs for patients and fortifying their market presence and competitiveness. Generic anticoagulant medicine helps to stop the formation of blood clots by interfering with different elements of the coagulation process, thereby decreasing the chances of stroke and other cardiovascular complications. For example, Tiefenbacher Pharmaceuticals, a healthcare firm based in Germany, introduced a generic version of Apixaban in Canada in October 2022. This orally administered anticoagulant is used for a range of applications including preventive measures post elective hip or knee replacement surgery, prevention of stroke in patients with atrial fibrillation, and the treatment of deep vein thrombosis and pulmonary embolism. The company, in its India-based laboratories, has developed 2.5 mg and 5 mg anticoagulant tablets to be distributed in Canada through collaboration with generic pharmaceutical companies, and plans to extend their launch to more international markets. This strategic initiative offers significant cost reduction for healthcare systems worldwide, and enhances access to essential treatments for a large number of patients.

Which Firms Are Driving Innovation Within The Apixaban Market?

Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Apixaban Market?

North America was the largest region in the apixaban market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15979&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model